What is Regenerative Ocular Immunobiologics?
Regenerative Ocular Immunobiologics (ROI) is a cutting-edge biotechnology company that is pioneering new therapeutic options in the field of ophthalmology. The company's primary focus is on developing regenerative medicines that can treat a range of ocular diseases, including ocular cancer, ocular graft versus host disease (oGVHD), and ocular toxicity.
​
This is a forward-thinking biotechnology company that is pushing the boundaries of regenerative medicine in the field of ophthalmology. With a focus on ocular cancer, oGVHD, and ocular toxicity, the company is poised to make a significant impact on the lives of patients suffering from these debilitating diseases.
Our Focus
The primary focus of Regenerative Ocular Immunobiologics (ROI) is to develop regenerative medicines that can treat ocular diseases, such as ocular cancer, ocular graft versus host disease (oGVHD), and ocular toxicity.
oGVHD
Ocular graft versus host disease (oGVHD) is a type of immune reaction that affects the eyes and can occur after a bone marrow transplant.
Ocular Toxicity
Ocular toxicity is a common side effect of many drugs used to treat ocular diseases. It occurs when the drugs accumulate in the eye, causing damage to the tissues.
Ocular Cancer
Ocular cancer is a rare form of cancer that can occur in the eye. The US sees 3.5K new cases of ocular cancer every year.